Livanova Plc OR Sh (LIVN)

$70.27 -0.33 (-0.47%)
Market Cap 3.86B
Revenue (ttm) 1.25B
Net Income (ttm) 63.23M
EPS (ttm) N/A
PE Ratio 20.70
Forward PE 19.85
Profit Margin 5.04%
Debt to Equity Ratio 0.38
Volume 856,300
Avg Vol 698,928
Day's Range N/A - N/A
Shares Out 54.69M
Stochastic %K 81%
Beta 0.97
Analysts Strong Sell
Price Target $80.50

Company Profile

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products and therapies for neurological and cardiac conditions worldwide. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related accessories. The Neuromodulation segment offers VNS Therapy...

Industry: Medical Devices
Sector: Healthcare
Phone: 44 20 3325 0660
Address:
20 Eastbourne Terrace, London, United Kingdom
BillionerOfKing
BillionerOfKing Mar. 3 at 2:37 AM
$LIVN Current Stock Price: $70.26 Contracts to trade: $70.0 LIVN Mar 20 2026 Call Entry: $0.95 Exit: $1.53 ROI: 61% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
erevnon
erevnon Feb. 27 at 4:55 PM
Barclays maintains LivaNova $LIVN at Equal-Weight and raises the price target from $67 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 26 at 8:33 PM
$LIVN RSI: 72.90, MACD: 1.6213 Vol: 1.86, MA20: 66.92, MA50: 64.57 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Estimize
Estimize Feb. 25 at 11:09 PM
$LIVN reported 0.86 EPS and 360.90 revenue for Q4. http://www.estimize.com/intro/livn?chart=historical&metric_name=eps&utm_content=LIVN&utm
0 · Reply
erevnon
erevnon Feb. 25 at 6:12 PM
Needham maintains LivaNova $LIVN at Buy and raises the price target from $64 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
briefingcom
briefingcom Feb. 25 at 1:12 PM
$LIVN: LivaNova beats by $0.04, beats on revs; guides FY26 EPS above consensus, revs in-line https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260225061017LIVN&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 25 at 11:13 AM
$LIVN Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.57 down -44.66% YoY • Reported revenue of $360.9M up 12.15% YoY • LivaNova PLC expects full-year 2026 revenue to grow 6.0% to 7.0% on a constant-currency basis. Adjusted diluted earnings per share is projected between $4.15 and $4.25, with adjusted free cash flow in the $160 million to $180 million range.
0 · Reply
CycleDriver
CycleDriver Feb. 18 at 3:50 PM
$LIVN LivaNova operates medical devices with exposure to cardiac and neuromodulation markets. Growth depends on procedural volumes and innovation pipeline. Margin improvement supports long-term outlook.
0 · Reply
LegacyLeverage
LegacyLeverage Feb. 4 at 9:17 AM
$LIVN medical devices, competitive markets
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 27 at 8:20 PM
$LIVN Current Stock Price: $63.92 Contracts to trade: $65 LIVN Feb 20 2026 Call Entry: $1.75 Exit: $2.25 ROI: 28% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Latest News on LIVN
Artisan International Small-Mid Fund Q4 2025 Performance Review

Mar 2, 2026, 1:38 PM EST - 8 hours ago

Artisan International Small-Mid Fund Q4 2025 Performance Review

CELC LEGN NICE

LivaNova PLC (LIVN) Q4 2025 Earnings Call Transcript

Feb 25, 2026, 5:27 PM EST - 5 days ago

LivaNova PLC (LIVN) Q4 2025 Earnings Call Transcript

LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance

Feb 25, 2026, 6:00 AM EST - 5 days ago

LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance

LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results

Jan 20, 2026, 9:00 AM EST - 5 weeks ago

LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results

LivaNova PLC (LIVN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 6:46 PM EST - 6 weeks ago

LivaNova PLC (LIVN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

LivaNova to Present at J.P. Morgan Healthcare Conference in January

Dec 23, 2025, 9:00 AM EST - 2 months ago

LivaNova to Present at J.P. Morgan Healthcare Conference in January

LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting

Dec 3, 2025, 9:00 AM EST - 3 months ago

LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting

LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea

Dec 2, 2025, 9:00 AM EST - 3 months ago

LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea

LivaNova to Present at Piper Sandler Healthcare Conference in December

Nov 25, 2025, 9:00 AM EST - 3 months ago

LivaNova to Present at Piper Sandler Healthcare Conference in December

LivaNova's VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services

Nov 24, 2025, 9:00 AM EST - 3 months ago

LivaNova's VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services

LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day

Nov 12, 2025, 3:26 PM EST - 3 months ago

LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day

LivaNova PLC (LIVN) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 3:41 PM EST - 4 months ago

LivaNova PLC (LIVN) Q3 2025 Earnings Call Transcript

LivaNova Reports Third-Quarter 2025 Results; Raises 2025 Guidance

Nov 5, 2025, 6:00 AM EST - 4 months ago

LivaNova Reports Third-Quarter 2025 Results; Raises 2025 Guidance

LivaNova to Present at Wolfe Research Healthcare Conference in November

Oct 23, 2025, 9:00 AM EDT - 4 months ago

LivaNova to Present at Wolfe Research Healthcare Conference in November

LivaNova: Robust Fundamentals, Long-Term Growth Potential

Oct 22, 2025, 11:50 PM EDT - 4 months ago

LivaNova: Robust Fundamentals, Long-Term Growth Potential

LivaNova to Announce Third-Quarter 2025 Results

Oct 8, 2025, 9:00 AM EDT - 5 months ago

LivaNova to Announce Third-Quarter 2025 Results

LivaNova to Present Scientific Data at International Surgical Sleep Society 2025 Annual Meeting

Oct 7, 2025, 9:00 AM EDT - 5 months ago

LivaNova to Present Scientific Data at International Surgical Sleep Society 2025 Annual Meeting

LivaNova PLC (LIVN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 4:00 PM EDT - 6 months ago

LivaNova PLC (LIVN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

LivaNova Appoints Donald Zurbay as a New Director

Sep 4, 2025, 9:00 AM EDT - 6 months ago

LivaNova Appoints Donald Zurbay as a New Director

LivaNova to Host Investor Day on November 12, 2025

Aug 25, 2025, 9:00 AM EDT - 6 months ago

LivaNova to Host Investor Day on November 12, 2025

LivaNova to Present at Baird and Morgan Stanley Global Healthcare Conferences in September

Aug 22, 2025, 9:00 AM EDT - 6 months ago

LivaNova to Present at Baird and Morgan Stanley Global Healthcare Conferences in September

LivaNova Launches Essenz Perfusion System in China

Aug 18, 2025, 9:00 AM EDT - 7 months ago

LivaNova Launches Essenz Perfusion System in China

LivaNova PLC (LIVN) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 11:18 PM EDT - 7 months ago

LivaNova PLC (LIVN) Q2 2025 Earnings Call Transcript

LivaNova Reports Second-Quarter 2025 Results; Raises 2025 Guidance

Aug 6, 2025, 6:00 AM EDT - 7 months ago

LivaNova Reports Second-Quarter 2025 Results; Raises 2025 Guidance

LivaNova to Announce Second-Quarter 2025 Results

Jul 9, 2025, 9:00 AM EDT - 8 months ago

LivaNova to Announce Second-Quarter 2025 Results

LivaNova: The Sell-Off Is Excessive Here

Jul 7, 2025, 1:34 PM EDT - 8 months ago

LivaNova: The Sell-Off Is Excessive Here

CORE-VNS Study Further Validates Effectiveness of LivaNova's VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy

Jun 5, 2025, 8:15 AM EDT - 9 months ago

CORE-VNS Study Further Validates Effectiveness of LivaNova's VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy

LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy

Jun 5, 2025, 8:00 AM EDT - 9 months ago

LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy

LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression

Jun 4, 2025, 8:00 AM EDT - 9 months ago

LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression

LivaNova to Present at the Jefferies Global Healthcare Conference

May 15, 2025, 8:00 AM EDT - 10 months ago

LivaNova to Present at the Jefferies Global Healthcare Conference

LivaNova PLC (LIVN) Q1 2025 Earnings Call Transcript

May 11, 2025, 2:56 AM EDT - 10 months ago

LivaNova PLC (LIVN) Q1 2025 Earnings Call Transcript

LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance

May 7, 2025, 6:00 AM EDT - 10 months ago

LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance

LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy

May 7, 2025, 5:45 AM EDT - 10 months ago

LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy

LivaNova to Announce First-Quarter 2025 Results

Mar 26, 2025, 8:00 AM EDT - 1 year ago

LivaNova to Announce First-Quarter 2025 Results

LivaNova PLC (LIVN) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 7:10 PM EST - 1 year ago

LivaNova PLC (LIVN) Q4 2024 Earnings Call Transcript

LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance

Feb 25, 2025, 6:00 AM EST - 1 year ago

LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance

LivaNova to Present at the Barclays Global Healthcare Conference

Feb 21, 2025, 9:00 AM EST - 1 year ago

LivaNova to Present at the Barclays Global Healthcare Conference

LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results

Jan 21, 2025, 9:00 AM EST - 1 year ago

LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results

RECOVER Clinical Study Shows Meaningful Benefits of LivaNova's VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression

Dec 18, 2024, 8:30 AM EST - 1 year ago

RECOVER Clinical Study Shows Meaningful Benefits of LivaNova's VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression

LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting

Dec 5, 2024, 9:00 AM EST - 1 year ago

LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting

LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences

Nov 14, 2024, 9:00 AM EST - 1 year ago

LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences

LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints

Nov 11, 2024, 4:05 PM EST - 1 year ago

LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints

LivaNova PLC (LIVN) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 2:30 PM EDT - 1 year ago

LivaNova PLC (LIVN) Q3 2024 Earnings Call Transcript

LivaNova Reports Third-Quarter 2024 Results

Oct 30, 2024, 6:00 AM EDT - 1 year ago

LivaNova Reports Third-Quarter 2024 Results

LivaNova: Economics Should Start Making Sustained Improvements

Oct 18, 2024, 3:45 AM EDT - 1 year ago

LivaNova: Economics Should Start Making Sustained Improvements

LivaNova Appoints Susan Podlogar as a New Director

Oct 8, 2024, 9:00 AM EDT - 1 year ago

LivaNova Appoints Susan Podlogar as a New Director

LivaNova's New Strategy Could Unlock Revenue, Profit Gains, Analyst Predicts

Oct 4, 2024, 11:59 AM EDT - 1 year ago

LivaNova's New Strategy Could Unlock Revenue, Profit Gains, Analyst Predicts

LivaNova to Announce Third-Quarter 2024 Results

Sep 25, 2024, 9:00 AM EDT - 1 year ago

LivaNova to Announce Third-Quarter 2024 Results

LivaNova to Present at the Baird Global Healthcare Conference

Aug 19, 2024, 9:00 AM EDT - 1 year ago

LivaNova to Present at the Baird Global Healthcare Conference

LivaNova PLC (LIVN) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 1:57 PM EDT - 1 year ago

LivaNova PLC (LIVN) Q2 2024 Earnings Call Transcript

BillionerOfKing
BillionerOfKing Mar. 3 at 2:37 AM
$LIVN Current Stock Price: $70.26 Contracts to trade: $70.0 LIVN Mar 20 2026 Call Entry: $0.95 Exit: $1.53 ROI: 61% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
erevnon
erevnon Feb. 27 at 4:55 PM
Barclays maintains LivaNova $LIVN at Equal-Weight and raises the price target from $67 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 26 at 8:33 PM
$LIVN RSI: 72.90, MACD: 1.6213 Vol: 1.86, MA20: 66.92, MA50: 64.57 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Estimize
Estimize Feb. 25 at 11:09 PM
$LIVN reported 0.86 EPS and 360.90 revenue for Q4. http://www.estimize.com/intro/livn?chart=historical&metric_name=eps&utm_content=LIVN&utm
0 · Reply
erevnon
erevnon Feb. 25 at 6:12 PM
Needham maintains LivaNova $LIVN at Buy and raises the price target from $64 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
briefingcom
briefingcom Feb. 25 at 1:12 PM
$LIVN: LivaNova beats by $0.04, beats on revs; guides FY26 EPS above consensus, revs in-line https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260225061017LIVN&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 25 at 11:13 AM
$LIVN Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.57 down -44.66% YoY • Reported revenue of $360.9M up 12.15% YoY • LivaNova PLC expects full-year 2026 revenue to grow 6.0% to 7.0% on a constant-currency basis. Adjusted diluted earnings per share is projected between $4.15 and $4.25, with adjusted free cash flow in the $160 million to $180 million range.
0 · Reply
CycleDriver
CycleDriver Feb. 18 at 3:50 PM
$LIVN LivaNova operates medical devices with exposure to cardiac and neuromodulation markets. Growth depends on procedural volumes and innovation pipeline. Margin improvement supports long-term outlook.
0 · Reply
LegacyLeverage
LegacyLeverage Feb. 4 at 9:17 AM
$LIVN medical devices, competitive markets
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 27 at 8:20 PM
$LIVN Current Stock Price: $63.92 Contracts to trade: $65 LIVN Feb 20 2026 Call Entry: $1.75 Exit: $2.25 ROI: 28% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
JarvisFlow
JarvisFlow Dec. 19 at 12:03 PM
Keybanc updates rating for LivaNova ( $LIVN ) to Overweight, target set at 81.
0 · Reply
JarvisFlow
JarvisFlow Dec. 17 at 3:05 PM
Mizuho updates rating for LivaNova ( $LIVN ) to Outperform, target set at 70 → 72.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 10 at 11:50 PM
$LIVN Current Stock Price: $64.06 Contracts to trade: $65 LIVN Dec 19 2025 Call Entry: $0.23 Exit: $0.31 ROI: 37% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Estimize
Estimize Nov. 27 at 11:00 AM
Wall St is expecting 0.81 EPS for $LIVN Q4 [Reporting 02/25 BMO] http://www.estimize.com/intro/livn?chart=historical&metric_name=eps&utm_co
0 · Reply
Doozio
Doozio Nov. 25 at 5:33 PM
It was always meant to be $LIVN during 🐒🍌🧠⏰♾️
0 · Reply
OphirMedia
OphirMedia Nov. 24 at 2:23 PM
$INSP rips after Medicare expands coverage for its sleep-apnea implant therapy. Reimbursement is everything in med-tech—this shifts demand modeling higher and extends TAM. $LIVN sympathy tailwinds.
0 · Reply
Mogeyman
Mogeyman Nov. 23 at 4:33 PM
$LIVN 2026 is the year.
0 · Reply
omarbryce
omarbryce Nov. 19 at 2:54 PM
$JD $LIVN $BE $GRRR The bullish trend is self-reinforcing, attracting more capital into the market. https://stocktwits.com/albertchristie/message/636687296
0 · Reply
THE_Perfusionist
THE_Perfusionist Nov. 14 at 2:34 AM
For those in the back…these companies like $MDT and $LIVN are rocking the ECMO world. $IINN not so much.
0 · Reply
erevnon
erevnon Nov. 13 at 1:03 PM
Baird maintains LivaNova $LIVN at Outperform and raises the price target from $63 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
JarvisFlow
JarvisFlow Nov. 13 at 12:38 PM
Mizuho has adjusted their stance on LivaNova ( $LIVN ), setting the rating to Outperform with a target price of 65 → 70.
0 · Reply
JarvisFlow
JarvisFlow Nov. 13 at 12:37 PM
Baird has updated their rating for LivaNova ( $LIVN ) to Outperform with a price target of 70.
0 · Reply